Development of a Metabolic Drug Interaction Database at the University of Washington

[1]  D. Flockhart,et al.  Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[2]  S. Binkley,et al.  In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A. , 1996, British journal of clinical pharmacology.

[3]  F. L. Wurden.  Content is king (If you can find it): a new model for knowledge storage and retrieval , 1997, Proceedings 13th International Conference on Data Engineering.

[4]  T. Cyr,et al.  Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole antifungals. , 1994, Drug metabolism and disposition: the biological fate of chemicals.

[5]  J. Beijnen,et al.  Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. , 1997, The Journal of clinical investigation.

[6]  R. Kim,et al.  Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A , 1999, Clinical pharmacology and therapeutics.

[7]  Kaoru Kobayashi,et al.  The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4'-hydroxylase activity in human liver microsomes. , 1995, British journal of clinical pharmacology.

[8]  D. Abernethy,et al.  Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19 , 1997, Clinical pharmacology and therapeutics.

[9]  S. Su,et al.  Inhibition of the intestinal digoxin absorption and exsorption by quinidine. , 1996, Drug Metabolism And Disposition.

[10]  T. Kamataki,et al.  Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4'-hydroxylation. , 1993, The Journal of pharmacology and experimental therapeutics.

[11]  Patrick Marroum,et al.  In vitro metabolic interaction studies: Experience of the Food and Drug Administration , 1999, Clinical pharmacology and therapeutics.

[12]  R. Woosley,et al.  Pharmacies and prevention of potentially fatal drug interactions. , 1996, JAMA.

[13]  T. Leemann,et al.  Quantitative drug interactions prediction system (Q-DIPS): a computer-based prediction and management support system for drug metabolism interactions , 1999, European Journal of Clinical Pharmacology.

[14]  P. Neuvonen,et al.  Itraconazole decreases renal clearance of digoxin. , 1997, Therapeutic drug monitoring.

[15]  R. Levy.  Cytochrome P450 Isozymes and Antiepileptic Drug Interactions , 1995, Epilepsia.